Validation of Cell-Cycle Arrest Biomarkers for Acute Kidney Injury Using Clinical Adjudication
Top Cited Papers
- 15 April 2014
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 189 (8), 932-939
- https://doi.org/10.1164/rccm.201401-0077oc
Abstract
Rationale: We recently reported two novel biomarkers for acute kidney injury (AKI), tissue inhibitor of metalloproteinases (TIMP)-2 and insulin-like growth factor binding protein 7 (IGFBP7), both related to G1 cell cycle arrest. Objectives: We now validate a clinical test for urinary [TIMP-2]·[IGFBP7] at a high-sensitivity cutoff greater than 0.3 for AKI risk stratification in a diverse population of critically ill patients. Methods: We conducted a prospective multicenter study of 420 critically ill patients. The primary analysis was the ability of urinary [TIMP-2]·[IGFBP7] to predict moderate to severe AKI within 12 hours. AKI was adjudicated by a committee of three independent expert nephrologists who were masked to the results of the test. Measurements and Main Results: Urinary TIMP-2 and IGFBP7 were measured using a clinical immunoassay platform. The primary endpoint was reached in 17% of patients. For a single urinary [TIMP-2]·[IGFBP7] test, sensitivity at the prespecified high-sensitivity cutoff of 0.3 (ng/ml)2/1,000 was 92% (95% confidence interval [CI], 85–98%) with a negative likelihood ratio of 0.18 (95% CI, 0.06–0.33). Critically ill patients with urinary [TIMP-2]·[IGFBP7] greater than 0.3 had seven times the risk for AKI (95% CI, 4–22) compared with critically ill patients with a test result below 0.3. In a multivariate model including clinical information, urinary [TIMP-2]·[IGFBP7] remained statistically significant and a strong predictor of AKI (area under the curve, 0.70, 95% CI, 0.63–0.76 for clinical variables alone, vs. area under the curve, 0.86, 95% CI, 0.80–0.90 for clinical variables plus [TIMP-2]·[IGFBP7]). Conclusions: Urinary [TIMP-2]·[IGFBP7] greater than 0.3 (ng/ml)2/1,000 identifies patients at risk for imminent AKI. Clinical trial registered with www.clinicaltrials.gov (NCT 01573962).Keywords
This publication has 34 references indexed in Scilit:
- Clinical Utility of a Novel Coronary Heart Disease Risk‐Assessment Test to Further Classify Intermediate‐Risk PatientsClinical Cardiology, 2013
- Acute kidney injury: an increasing global concernThe Lancet, 2013
- Design of Clinical Trials in AKIClinical Journal of the American Society of Nephrology, 2012
- Design of Clinical Trials in Acute Kidney InjuryClinical Journal of the American Society of Nephrology, 2012
- Design of Clinical Trials in Acute Kidney InjuryClinical Journal of the American Society of Nephrology, 2012
- The severity of acute kidney injury predicts progression to chronic kidney diseaseKidney International, 2011
- Sensitive Troponin I Assay in Early Diagnosis of Acute Myocardial InfarctionThe New England Journal of Medicine, 2009
- Acute Kidney Injury Increases Risk of ESRD among ElderlyJournal of the American Society of Nephrology, 2009
- Early acute kidney injury and sepsis: a multicentre evaluationCritical Care, 2008
- Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized PatientsJournal of the American Society of Nephrology, 2005